Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Cognitive behavioural therapy reduces supragrastic belching

15 Apr 2018

Cognitive behavioural therapy (CBT) appears to be effective in reducing supragastric belching (SGB) and improving quality of life (QoL), such as in daily and social activities, a recent study has shown.

CBT resulted in a significant decline in SGB, from a median of 116 episodes at baseline to 45 episodes after five CBT sessions (p=0.0003). In more than half of the participants (n=16), total number of SGB episodes decreased by more than 50 percent.

A significant decrease in the total number of acid and nonacid reflux episodes from baseline (71±43 to 54±39; p=0.0055) was observed after CBT. In 17 patients with pathological acid exposure at baseline, CBT likewise led to significant improvements (acid exposure from 9.0±3.2 percent to 6.1±3.5 percent; p=0.0053).

In terms of subjective measures, self-reported belching severity improved significantly following 8 weeks of CBT, as measured by median visual analogue scale scores (260 to 140; p<0.0001). Reduction of 50 percent was recorded in 51 percent.

There was also an associated improvement in QoL scores in the general health, vitality, and physical and social function domains of the Short-Form Health Survey following CBT (p<0.05).

For the study, researchers recruited 39 patients with SGB, of whom 31 agreed to a follow-up examination. Study outcomes included objective measures, such as the number of SGBs and acid exposure time, and subjective measures such as QoL.

CBT sessions included psychoeducation about SGB, increasing the patients’ awareness of the factors that contribute to belching. Prevention exercises, such as diaphragmatic breathing and tongue positioning, were also taught to the participants.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.